

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
15 April 2004 (15.04.2004)

PCT

(10) International Publication Number  
**WO 2004/031193 A1**

(51) International Patent Classification<sup>7</sup>: **C07D 495/04**,  
333/36 // (C07D 495/04, 333:00, 209:00)

Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). **STOCKER, Andrew** [GB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).

(21) International Application Number:  
PCT/GB2003/004211

(74) Agent: **ASTRAZENECA**; Global Intellectual Property, P O Box 272, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4GR (GB).

(22) International Filing Date:  
29 September 2003 (29.09.2003)

(25) Filing Language: English

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(26) Publication Language: English

(30) Priority Data:  
0222909.4 3 October 2002 (03.10.2002) GB

(71) Applicant (*for AE, AG, AL, AM, AT, AU, AZ, BA, BB, BE, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CY, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, FR, GB, GD, GE, GH, GM, GR, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, SZ, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW only*): **ASTRAZENECA AB** [SE/SE]; Sodertalje, S-151 85 (SE).

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for MG only*): **ASTRAZENECA UK LIMITED** [GB/GB]; 15 Stanhope Gate, London, Greater London W1K 1LN (GB).

**Published:**


- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(72) Inventors; and


(75) Inventors/Applicants (*for US only*): **BUTTERS, Michael** [GB/GB]; AstraZeneca, Avlon Works, Severn Road, Hallen, Bristol, Avon BS10 7ZE (GB). **SCHOFIELD, Paul** [GB/GB]; AstraZeneca R & D

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PROCESS AND INTERMEDIATES FOR THE PREPARATION OF THIENOPYRROLE DERIVATIVES



(I)



(II)

(57) Abstract: Novel Process and Intermediates. A process for preparing a compound of formula (I) where R<sup>4</sup> and R<sup>5</sup> are as defined in the specification; and R<sup>6</sup> is hydrogen or a protecting group, which process comprises cyclisation of a compound of formula (II) where R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> are as defined in relation to formula (I), and R<sup>7</sup> is a nitrogen protecting group, and removing the group R<sup>7</sup>, and thereafter if desired, removing any protecting group R<sup>6</sup>. Novel intermediates and the use of these in the formation of pharmaceutical compounds is also described and claimed.




WO 2004/031193 A1

PROCESS AND INTERMEDIATES FOR  
THE PREPARATION OF THIENOPYRROLE DERIVATIVES

The present invention relates to a novel process for preparing intermediates for therapeutically effective compounds, together with novel intermediates for use in the process.


- 5        Compounds with glycogen phosphorylase activity are described in WO 02/20530. These compounds have a general formula which may be represented as formula (A)



(A)

- where X, Y and Z is selected from *inter alia*  $-S-CR^4=CR^5-$ ,  $R^4$  and  $R^5$  are independently  
10 selected from hydrogen, halo, nitro, cyano, hydroxy, fluoromethyl, difluoromethyl, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, ureido,  $C_{1-6}$ alkyl,  $C_{2-6}$ alkenyl,  $C_{2-6}$ alkynyl,  $C_{1-6}$ alkoxy,  $C_{1-6}$ alkanoyl,  $C_{1-6}$ alkanoyloxy,  $N-(C_{1-6}$ alkyl)amino,  $N,N-(C_{1-6}$ alkyl) $_2$ amino,  $C_{1-6}$ alkanoylamino,  $N-(C_{1-6}$ alkyl)carbamoyl,  $N,N-(C_{1-6}$ alkyl) $_2$ carbamoyl,  $C_{1-6}$ alkylS(O) $_a$  wherein a is 0 to 2,  $C_{1-6}$ alkoxycarbonyl,  
15  $C_{1-6}$ alkoxycarbonylamino,  $N-(C_{1-6}$ alkyl)sulphamoyl,  $N,N-(C_{1-6}$ alkyl) $_2$ sulphamoyl,  $C_{1-6}$ alkylsulphonylamino and  $C_{1-6}$ alkylsulphonyl- $N-(C_{1-6}$ alkyl)amino;  
n is 0-4, and  $R^1$ ,  $R^2$  and  $R^3$  are various specified organic groups.


These compounds are generally prepared by reacting an acid of formula (B)



(B)

- 20 with an appropriate amine. Acids of formula (B) are prepared according to the following scheme:


- 2 -



However, this process is difficult to effect as it may proceed explosively.


The applicants have found an improved process for the production of certain  
5 intermediates.

The present invention provides a process for preparing a compound of formula (I)



where  $R^4$  and  $R^5$  are independently selected from hydrogen, halo, nitro, cyano, hydroxy,  
10 fluoromethyl, difluoromethyl, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl,  
mercapto, sulphamoyl, ureido,  $C_{1-6}$ alkyl,  $C_{2-6}$ alkenyl,  $C_{2-6}$ alkynyl,  $C_{1-6}$ alkoxy,  $C_{1-6}$ alkanoyl,  
 $C_{1-6}$ alkanoyloxy,  $N$ -( $C_{1-6}$ alkyl)amino,  $N,N$ -( $C_{1-6}$ alkyl) $_2$ amino,  $C_{1-6}$ alkanoylamino,  $N$ -( $C_{1-6}$ alkyl)carbamoyl,  $N,N$ -( $C_{1-6}$ alkyl) $_2$ carbamoyl,  $C_{1-6}$ alkylS(O) $_a$  wherein  $a$  is 0 to 2,  $C_{1-6}$ alkoxycarbonyl,  $C_{1-6}$ alkoxycarbonylamino,  $N$ -( $C_{1-6}$ alkyl)sulphamoyl,  $N,N$ -( $C_{1-6}$ alkyl) $_2$ sulphamoyl,  $C_{1-6}$ alkylsulphonylamino and  $C_{1-6}$ alkylsulphonyl- $N$ -( $C_{1-6}$ alkyl)amino;  
15 and  $R^6$  is hydrogen or a protecting group,

which process comprises cyclisation of a compound of formula (II)




where  $R^4$ ,  $R^5$  and  $R^6$  are as defined in relation to formula (I), and  $R^7$  is a nitrogen-protecting group, and removing the group  $R^7$ , and thereafter if desired, removing any protecting group  $R^6$ .

Cyclisation is suitably effected in an organic solvent such as dimethylformamide (DMF), N-methylpyrrolidone or dimethylacetamide, in the presence of a base, preferably a weak base such as an alkali metal carbonate or bicarbonate, such as potassium carbonate. The reaction is suitably carried out at elevated temperatures, for example of from 40 to 100°C, and preferably at about 60°C. Under these conditions,  $R^7$  is generally removed in the same reaction step. Depending upon the nature of the group employed however, it might be necessary to remove  $R^7$  in a subsequent step, for example by acid or base hydrolysis reactions.

Acid hydrolysis reactions may be carried out using conventional methods, and in particular using acids such as trifluoromethanesulphonic acid, acetic acid or hydrochloric acid. Base hydrolysis reactions are suitably effected in the presence of bases, such as alkali metal hydrides or hydroxides, and in particular sodium or potassium hydroxide.

Suitable example of protecting groups  $R^7$  are listed in T.W. Green, Protecting Groups in Organic Synthesis, J. Wiley and Sons, 1991 and in particular are those designated as nitrogen protection groups.

Particular examples of protecting groups  $R^7$  are groups of sub-formula (i)



(i)

where  $R^8$  is a hydrocarbyl or heterocyclic group, either of which may be optionally substituted.

As used herein, the expression “hydrocarbyl” includes any structure comprising carbon and hydrogen atoms. For example, these may be alkyl, alkenyl, alkynyl, aryl such as phenyl or naphthyl, arylalkyl such as benzyl, or cycloalkyl, cycloalkenyl or cycloalkynyl. Suitably hydrocarbyl groups contain up to 20 and preferably up to 10 carbon atoms.

The term “aryl” refers to aromatic rings such as phenyl or naphthyl.

The term “heterocyclic” includes aromatic or non-aromatic rings, for example containing from 4 to 20, suitably from 5 to 8 ring atoms, at least one of which, and suitably from 1 to 4 of which is a heteroatom such as oxygen, sulphur or nitrogen. They may be monocyclic or have fused rings, such a bicyclic or tricyclic ring systems. Examples of such groups include furyl, thienyl, pyrrolyl, pyrrolidinyl, imidazolyl, triazolyl, thiazolyl, tetrazolyl,

oxazolyl, isoxazolyl, piperidinyl, pyrazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, quinolinyl, isoquinolinyl, quinoxalyl, benzothiazolyl, benzoxazolyl, benzothieryl or benzofuryl.


The term "heteroaryl" refers to heterocyclic groups which are aromatic in nature.

- 5 Thus these may comprises cyclic aromatic hydrocarbons in which one or more carbon atoms have been replaced with a heteroatom. If the heteroaryl group contains more than one heteroatom, the heteroatoms may be the same or different. Examples of heteroaryl groups include pyridyl, pyrimidinyl, imidazolyl, thienyl, furyl, pyrazinyl, pyrrolyl, pyranal, isobenzofuranyl, chromenyl, xanthenyl, indolyl, isoindolyl, indoliziny, triazolyl, pyridazinyl, 10 indazolyl, purinyl, quinioliziny, isoquinolyl, quinolyl phthalazinyl, naphthyridinyl, quinoxalyl, isothiazolyl and benzo[b]thienyl. Preferred heteroaryl groups are five or six membered rings and contain from one to three heteroatoms.

- Suitable optional substituents for heterocyclic and hydrocarbyl groups  $R^8$  include nitro, cyano, halo, oxo,  $=CR^{13}R^{14}$ ,  $C(O)_xR^{12}$ ,  $OR^{12}$ ,  $S(O)_yR^{12}$ ,  $NR^{13}R^{14}$ ,  $C(O)NR^{13}R^{14}$ , 15  $OC(O)NR^{13}R^{14}$ ,  $=NOR^{12}$ ,  $-NR^{12}C(O)_xR^{13}$ ,  $-NR^{12}CONR^{13}R^{14}$ ,  $-N=CR^{13}R^{14}$ ,  $S(O)_yNR^{13}R^{14}$  or  $-NR^{12}S(O)_yR^{13}$  where  $R^{12}$ ,  $R^{13}$  and  $R^{14}$  are independently selected from hydrogen or optionally substituted hydrocarbyl, or  $R^{13}$  and  $R^{14}$  together form an optionally substituted ring which optionally contains further heteroatoms such as  $S(O)_y$  oxygen and nitrogen, x is an integer of 1 or 2, y is 0 or an integer of 1-3. Hydrocarbyl groups  $R^8$  may also include 20 heterocyclic substituents, which may themselves be optionally substituted by one or more of the optional substituents listed above. Heterocyclic groups may also be substituted with hydrocarbyl groups which may also be optionally substituted by any of the groups listed above.

- Preferably  $R^8$  is a hydrocarbyl group such as alkyl, aryl or arylalkyl. Most preferably 25  $R^8$  is a straight chain alkyl group of from 1 to 6 carbon atoms, and particularly is a straight chain  $C_{1-4}$ alkyl group, such as methyl.

Examples of protecting groups  $R^7$  are groups of sub-formula (i)



30

(i)

where  $R^8$  is a straight chain alkyl group of from 1 to 6 carbon atoms, and particularly is a straight chain  $C_{1-4}$ alkyl group, such as methyl.

Particular examples of ester protecting groups  $R^6$  are any organic groups which can be removed by hydrogenation or hydrolysis. These include optionally substituted hydrocarbyl or optionally substituted heterocyclic groups. Such groups may be similar to those listed above in relation to  $R^7$ .

- 5            Suitable example of protecting groups  $R^6$  are also listed in T.W. Green, Protecting Groups in Organic Synthesis, J. Wiley and Sons, 1991 and in particular are those designated as acid protecting groups.

In particular  $R^6$  is a hydrocarbyl group such as  $C_{1-6}$ alkyl,  $C_{2-6}$ alkenyl,  $C_{2-6}$ alkynyl, aryl such as phenyl, or arylalkyl such as benzyl.

- 10           Conversion of a protecting group  $R^6$  to hydrogen is suitably effected using conventional methods, for example as described in WO 02/20530. In particular, the compound is reacted with a base such as lithium hydroxide, in an organic solvent such as methanol, at temperatures of from 20-80°C, and conveniently at the reflux temperature of the solvent.

- 15           Particular examples of groups  $R^4$  and  $R^5$  are hydrogen, halo, nitro, cyano, fluoromethyl, difluoromethyl, trifluoromethyl, trifluoromethoxy, carboxy, carbamoyl, sulphamoyl, ureido,  $C_{1-6}$ alkyl,  $C_{2-6}$ alkenyl,  $C_{2-6}$ alkynyl,  $C_{1-6}$ alkoxy,  $C_{1-6}$ alkanoyl and  $C_{1-6}$ alkanoyloxy.


- 20           Suitably  $R^4$  and  $R^5$  are independently selected from hydrogen, halo, nitro, cyano, fluoromethyl, difluoromethyl, trifluoromethyl, trifluoromethoxy, carboxy, carbamoyl, sulphamoyl,  $C_{1-4}$ alkyl,  $C_{2-4}$ alkenyl,  $C_{2-4}$ alkynyl,  $C_{1-4}$ alkoxy,  $C_{1-4}$ alkanoyl, and  $C_{1-4}$ alkanoyloxy.

Preferably  $R^4$  and  $R^5$  are independently selected from hydrogen and halo such as chloro, fluoro and bromo, and in particular chloro.

- 25           Most preferably  $R^4$  and  $R^5$  are halo such as chloro.

Compounds of formula (II) are suitably prepared by reacting a compound of formula (III)

- 6 -



(III)

where  $R^4$ ,  $R^5$  and  $R^6$  are as defined in relation to formula (I), and  $R^{12}$  is a directing nitrogen-protecting group, with a compound of formula (IV)




where  $R^7$  is as defined above, under acidic condition, for example in a solvent comprising an organic acid, such as acetic acid. Elevated temperatures for example of from 80-150°C and preferably from 110-130°C are employed.

10 Directing nitrogen protecting groups are groups which may act as nitrogen protecting groups, but are sufficiently bulky in nature to prevent any substitution on the nitrogen atom, or the ring atom to which it is attached. Reactions, for example deprotonation by an organolithium reagent, are thereby directed to the adjacent position on the ring. Thus particular examples of nitrogen directing groups  $R^{12}$  are groups of sub-formula (ii)




where  $R^{14}$  is a branched  $C_{4-10}$ alkyl group such as tertiary butyl, or an aryl or  $C_{1-4}$ alkylaryl group such as benzyl.

20 Compounds of formula (III) are suitably prepared by reacting a compound of formula (V)




- 7 -

where  $R^4$  and  $R^5$  are as defined above in relation to formula (I) and  $R^{12}$  is as defined in relation to formula (III), with a compound of formula (VI)




5 where L is a leaving group such as halogen and in particular bromine. The reaction is suitably effected in the presence of a base such as an alkali metal carbonate, bicarbonate, hydroxide or alkoxide, for instance potassium bicarbonate in an organic solvent such as dimethylformamide. The reaction may be conducted at elevated temperatures, for example of from 40 to 100°C, preferably from 50 to 70°C and most preferably at about 60°C.

10 Compounds of formula (V) are suitably prepared by a directed ortho metallation reaction (J. Org. Chem. 20001, 66, 3662-3670). In this case, the compound of formula (V) is prepared by reacting a compound of formula (VII)



where  $R^4$  and  $R^5$  are as defined in relation to formula (I) and  $R^{12}$  is as defined in relation to formula (III), with a lithiating agent, such as N-butyl lithium, and subsequently with a formylating agent, such as a compound of formula (VIII)




where  $R^9$  and  $R^{10}$  are alkyl groups and in particular lower alkyl groups of 1 to 4 carbon atoms, such as methyl. Reaction with the lithiating agent is suitably effected in an organic solvent such as tetrahydrofuran (THF), at low temperatures for example of from -100° to 0°C and preferably from -80° to -10°C. The subsequent addition of the formylating agent is suitably also effected at low temperatures, but in this case, temperatures of from -20° to 0°C are adequate.

Compounds of formula (VII) are suitably prepared by subjecting a compound of formula (IX)




- 8 -



(IX)

where  $R^4$  and  $R^5$  are as defined above in relation to formula (I), to a Curtius rearrangement reaction, in the presence of an alcohol of formula  $R^{14}OH$  where  $R^{14}$  is as defined in relation to formula (ii). In this reaction, the compound of formula (IX) is reacted with


5 diphenylphosphorylazide of formula (X)



(X)

to convert the acid group to a carbonyl azide, which is thermally decomposed to the desired amide via an isocyanate. Suitable reaction conditions are illustrated hereinafter. The reaction is suitably effected in the presence of a base such as triethylamine.

10 Compounds of formula (IX) are suitably prepared by oxidation of a compound of formula (XI)




(XI)

where  $R^4$  and  $R^5$  are as defined in relation to formula (I) for example using an oxidising agent such as potassium permanganate in the presence of a base such as an alkali metal hydroxide

15 such as sodium hydroxide. The reaction is suitably effected in an aqueous solvent at moderate temperatures for example of from 10 to 80°C and preferably at about 40°C.

Compounds of formula (XI) where  $R^4$  and  $R^5$  are halogen can be prepared by halogenation of compounds of formula (XII)



(XII)


Suitably this is effected using a halogenating agent such as chlorine and aluminium trichloride, in an organic solvent such as dichloromethane.

Compounds of formula (II), (III), (V) and (VII) are novel and form further aspects of the invention.

- 5 Compounds of formula (IV), (VI), (VIII), (IX), (X), (XI) and (XII) are known compounds or they can be prepared from known compounds by conventional methods.

Compounds of formula (I) are suitably used in the production of pharmaceutical compounds and in particular, compounds with glycogen phosphorylase activity as described in WO 02/20530 and EP-A-1088824.

- 10 Thus in a further aspect, the invention provides a method as described above, for the production of a compound of formula (I) where  $R^6$  is hydrogen, and further comprising reacting the compound of formula (I) obtained with an amine of formula (XIII),



(XIII)

- 15 where  $R^{14}$  is selected from hydrogen and  $C_{1-8}$ alkyl,  
 $m$  is an integer of from 0 to 4,  
each  $R^{15}$  is the same or different and is selected from hydrogen, halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, ureido,  $C_{1-6}$ alkyl,  $C_{2-6}$ alkenyl,  $C_{2-6}$ alkynyl,  $C_{1-6}$ alkoxy,  $C_{1-6}$ alkanoyl,  $C_{1-6}$ alkanoyloxy,  $N$ -( $C_{1-6}$ alkyl)amino,  $N,N$ -( $C_{1-6}$ alkyl)<sub>2</sub>amino,  
20  $C_{1-6}$ alkanoylamino,  $N$ -( $C_{1-6}$ alkyl)carbamoyl,  $N,N$ -( $C_{1-4}$ alkyl)<sub>2</sub>carbamoyl,  $C_{1-6}$ alkylS(O)<sub>a</sub>  
wherein  $a$  is 0 to 2,  $C_{1-6}$ alkoxycarbonyl,  $C_{1-6}$ alkoxycarbonylamino,  $N$ -( $C_{1-6}$ alkyl)sulphamoyl,  $N,N$ -( $C_{1-6}$ alkyl)<sub>2</sub>sulphamoyl,  $C_{1-6}$ alkylsulphonylamino,  
 $C_{1-6}$ alkylsulphonyl- $N$ -( $C_{1-6}$ alkyl)amino,  $C_{3-8}$ cycloalkyl,  $C_{3-8}$ cycloalkyl $C_{1-6}$ alkyl, aryl,  
aryl $C_{1-6}$ alkyl, heterocyclic group and (heterocyclic group) $C_{1-6}$ alkyl; wherein  $R^{15}$  may be  
25 optionally substituted on carbon by one or more groups selected from P and wherein if said heterocyclic group contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R;  
each  $R^{16}$  is the same or different and is selected from hydrogen and  $C_{1-6}$ alkyl;  
 $R^{17}$  is selected from hydrogen, halo, nitro, cyano, hydroxy, fluoromethyl,  
30 difluoromethyl, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, ureido,  $C_{1-6}$ alkyl,  $C_{2-6}$ alkenyl,  $C_{2-6}$ alkynyl,  $C_{1-6}$ alkoxy,  $C_{1-6}$ alkanoyl,

C<sub>1-6</sub>alkanoyloxy, *N*-(C<sub>1-6</sub>alkyl)amino, *N,N*-(C<sub>1-6</sub>alkyl)<sub>2</sub>amino, C<sub>1-6</sub>alkanoylamino, *N*-(C<sub>1-6</sub>alkyl)carbamoyl, *N,N*-(C<sub>1-4</sub>alkyl)<sub>2</sub>carbamoyl, *N*-(C<sub>1-6</sub>alkyl)-*N*-(C<sub>1-6</sub>alkoxy)carbamoyl, C<sub>1-6</sub>alkylS(O)<sub>a</sub> wherein a is 0 to 2, C<sub>1-6</sub>alkoxycarbonyl, C<sub>1-6</sub>alkoxycarbonylamino, *N*-(C<sub>1-6</sub>alkyl)sulphamoyl, *N,N*-(C<sub>1-6</sub>alkyl)<sub>2</sub>sulphamoyl, sulphamoylamino, 5 *N*-(C<sub>1-6</sub>alkyl)sulphamoylamino, *N,N*-(C<sub>1-6</sub>alkyl)<sub>2</sub>sulphamoylamino, C<sub>1-6</sub>alkylsulphonylamino, C<sub>1-6</sub>alkylsulphonylaminocarbonyl, C<sub>1-6</sub>alkylsulphonyl-*N*-(C<sub>1-6</sub>alkyl)amino and a group -E-F-G-H;

wherein E and G are independently selected from a direct bond, -O-, -S-, -SO-, -SO<sub>2</sub>-, -OC(O)-, -C(O)O-, -C(O)-, -NR<sup>a</sup>-, -NR<sup>a</sup>C(O)-, -C(O)NR<sup>a</sup>-, -SO<sub>2</sub>NR<sup>a</sup>-, -NR<sup>a</sup>SO<sub>2</sub>-, 10 -NR<sup>a</sup>C(O)NR<sup>b</sup>-, -OC(O)NR<sup>a</sup>-, -NR<sup>a</sup>C(O)O-, -NR<sup>a</sup>SO<sub>2</sub>NR<sup>b</sup>-, -SO<sub>2</sub>NR<sup>a</sup>C(O)- and -C(O)NR<sup>a</sup>SO<sub>2</sub>-; wherein R<sup>a</sup> and R<sup>b</sup> are independently selected from hydrogen or C<sub>1-6</sub>alkyl which is optionally substituted by a group V;

F is C<sub>1-6</sub>alkylene optionally substituted by one or more Q or a direct bond;

H is selected from aryl, C<sub>3-8</sub>cycloalkyl and heterocyclic group; wherein H may be 15 optionally substituted on carbon by one or more groups selected from S and wherein if said heterocyclic group contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from T;


P, S and Q are independently selected from halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, ureido, 20 C<sub>1-6</sub>alkyl, C<sub>2-6</sub>alkenyl, C<sub>2-6</sub>alkynyl, C<sub>1-6</sub>alkoxy, C<sub>1-6</sub>alkanoyl, C<sub>1-6</sub>alkanoyloxy, *N*-(C<sub>1-6</sub>alkyl)amino, *N,N*-(C<sub>1-6</sub>alkyl)<sub>2</sub>amino, C<sub>1-6</sub>alkanoylamino, *N*-(C<sub>1-6</sub>alkyl)carbamoyl, *N,N*-(C<sub>1-6</sub>alkyl)<sub>2</sub>carbamoyl, *N*-(C<sub>1-6</sub>alkyl)-*N*-(C<sub>1-6</sub>alkoxy)carbamoyl, C<sub>1-6</sub>alkylS(O)<sub>a</sub> wherein a is 0 to 2, C<sub>1-6</sub>alkoxycarbonyl, C<sub>1-6</sub>alkoxycarbonylamino, *N*-(C<sub>1-6</sub>alkyl)sulphamoyl, *N,N*-(C<sub>1-6</sub>alkyl)<sub>2</sub>sulphamoyl, C<sub>1-6</sub>alkylsulphonylamino, 25 C<sub>1-6</sub>alkylsulphonyl-*N*-(C<sub>1-6</sub>alkyl)amino, C<sub>3-8</sub>cycloalkyl, aryl and heterocyclic group; wherein P, S and Q may be optionally and independently substituted on carbon by one or more groups selected from V and wherein if said heterocyclic group contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from U;

V is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, 30 amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxymethyl, methylamino, ethylamino, dimethylamino, diethylamino, *N*-methyl-*N*-ethylamino, acetylamino, *N*-methylcarbamoyl, *N*-ethylcarbamoyl, *N,N*-dimethylcarbamoyl, *N,N*-diethylcarbamoyl, *N*-methyl-*N*-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl,

ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, *N*-methylsulphamoyl, *N*-ethylsulphamoyl, *N,N*-dimethylsulphamoyl, *N,N*-diethylsulphamoyl, *N*-methyl-*N*-ethylsulphamoyl, morpholino, morpholinocarbonyl, *N*-benzylcarbamoyl, and 4-hydroxypiperidinocarbonyl;

5 R, T and U are independently selected from C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkanoyl, C<sub>1-4</sub>alkylsulphonyl, C<sub>1-4</sub>alkoxycarbonyl, carbamoyl, *N*-(C<sub>1-4</sub>alkyl)carbamoyl, *N,N*-(C<sub>1-4</sub>alkyl)carbamoyl, phenyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl wherein R, T and U may be optionally and independently substituted on carbon by one or more groups selected from V;

10 to produce a compound of formula (XIV)



(XIV)

where R<sup>4</sup>, R<sup>5</sup>, R<sup>15</sup>, R<sup>16</sup>, R<sup>17</sup> and m are as defined above, or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

15 Particular examples of compounds of formula (XIV) are compounds where R<sup>14</sup> is hydrogen, as described in WO 02/20530. For instance, suitable compounds of formula (XIV) are compounds where R<sup>4</sup> and R<sup>5</sup> are as defined above, R<sup>14</sup> is hydrogen, m is 0 and R<sup>17</sup> is a group -E-F-G-H;

wherein E, F and G are each a direct bond;

20 H is a C<sub>3-12</sub>cycloalkyl which is optionally fused to a benz ring wherein H may be optionally substituted on carbon by one or more groups S which are independently selected from halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, ureido, C<sub>1-6</sub>alkyl, C<sub>2-6</sub>alkenyl, C<sub>2-6</sub>alkynyl, C<sub>1-6</sub>alkoxy, C<sub>1-6</sub>alkanoyl, C<sub>1-6</sub>alkanoyloxy, *N*-(C<sub>1-6</sub>alkyl)amino, *N,N*-(C<sub>1-6</sub>alkyl)<sub>2</sub>amino, 25 C<sub>1-6</sub>alkanoylamino, *N*-(C<sub>1-6</sub>alkyl)carbamoyl, *N,N*-(C<sub>1-6</sub>alkyl)<sub>2</sub>carbamoyl, *N*-(C<sub>1-6</sub>alkyl)-*N*-(C<sub>1-6</sub>alkoxy)carbamoyl, C<sub>1-6</sub>alkylS(O)<sub>a</sub> wherein a is 0 to 2, C<sub>1-6</sub>alkoxycarbonyl, C<sub>1-6</sub>alkoxycarbonylamino, *N*-(C<sub>1-6</sub>alkyl)sulphamoyl, *N,N*-(C<sub>1-6</sub>alkyl)<sub>2</sub>sulphamoyl, C<sub>1-6</sub>alkylsulphonylamino, C<sub>1-6</sub>alkylsulphonyl-*N*-(C<sub>1-6</sub>alkyl)amino, C<sub>3-8</sub>cycloalkyl, aryl and heterocyclic groups; wherein 30 S may be optionally substituted on carbon by one or more groups selected from V;

V is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxymethyl, methylamino, ethylamino, dimethylamino, diethylamino, *N*-methyl-*N*-ethylamino, acetylamino, *N*-methylcarbamoyl, *N*-ethylcarbamoyl, *N,N*-dimethylcarbamoyl,


- 5 *N,N*-diethylcarbamoyl, *N*-methyl-*N*-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, *N*-methylsulphamoyl, *N*-ethylsulphamoyl, *N,N*-dimethylsulphamoyl, *N,N*-diethylsulphamoyl, *N*-methyl-*N*-ethylsulphamoyl, morpholino, morpholinocarbonyl, *N*-benzylcarbamoyl, and 4-hydroxypiperidinocarbonyl;

- 10 or a pharmaceutically acceptable salt thereof.

Other suitable compounds of formula (XIV) are compounds where  $R^4$  and  $R^5$  are as defined above,  $R^{14}$  is hydrogen,  $m$  is 0, and  $R^{17}$  is a group -E-F-G-H;

wherein E, F and G are each a direct bond; and

H is a cyclic amide of formula



15

in which the point of attachment is the carbon atom adjacent to the carbonyl group,  $k$  is 0, 1 or 2 and  $l$  is 0, 1 or 2 such that the sum of  $(k + l)$  is 1, 2 or 3 and wherein one of the carbon atoms governed by  $k$  or  $l$  may be replaced by sulphur and wherein H is optionally substituted on the carbon atom adjacent to the aromatic ring by a group selected from S and may be

- 20 independently optionally substituted on nitrogen by a group selected from T;

S is selected from halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, ureido,  $C_{1-6}$ alkyl,  $C_{2-6}$ alkenyl,  $C_{2-6}$ alkynyl,  $C_{1-6}$ alkoxy,  $C_{1-6}$ alkanoyl,  $C_{1-6}$ alkanoyloxy, *N*-( $C_{1-6}$ alkyl)amino, *N,N*-( $C_{1-6}$ alkyl)<sub>2</sub>amino,  $C_{1-6}$ alkanoylamino, *N*-( $C_{1-6}$ alkyl)carbamoyl, *N,N*-( $C_{1-6}$ alkyl)<sub>2</sub>carbamoyl,

- 25 *N*-( $C_{1-6}$ alkyl)-*N*-( $C_{1-6}$ alkoxy)carbamoyl,  $C_{1-6}$ alkylS(O)<sub>a</sub> wherein  $a$  is 0 to 2,

$C_{1-6}$ alkoxycarbonyl,  $C_{1-6}$ alkoxycarbonylamino, *N*-( $C_{1-6}$ alkyl)sulphamoyl,

*N,N*-( $C_{1-6}$ alkyl)<sub>2</sub>sulphamoyl,  $C_{1-6}$ alkylsulphonylamino,

$C_{1-6}$ alkylsulphonyl-*N*-( $C_{1-6}$ alkyl)amino,  $C_{3-8}$ cycloalkyl, aryl and heterocyclic group; wherein S may be optionally and independently substituted on carbon by one or more groups selected

- 30 from V and wherein if said heterocyclic group contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from U;

T and U are independently selected from C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkanoyl, C<sub>1-4</sub>alkylsulphonyl, C<sub>1-4</sub>alkoxycarbonyl, carbamoyl, *N*-(C<sub>1-4</sub>alkyl)carbamoyl, *N,N*-(C<sub>1-4</sub>alkyl)carbamoyl, phenyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl wherein R, T and U may be optionally and independently substituted on carbon by one or more groups selected from V;

5 V is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxymethyl, methylamino, ethylamino, dimethylamino, diethylamino, *N*-methyl-*N*-ethylamino, acetylamino, *N*-methylcarbamoyl, *N*-ethylcarbamoyl, *N,N*-dimethylcarbamoyl, *N,N*-diethylcarbamoyl, *N*-methyl-*N*-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, *N*-methylsulphamoyl, *N*-ethylsulphamoyl, *N,N*-dimethylsulphamoyl, *N,N*-diethylsulphamoyl, *N*-methyl-*N*-ethylsulphamoyl, morpholino, morpholinocarbonyl, *N*-benzylcarbamoyl and 4-hydroxypiperidinocarbonyl ;

or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

15 Yet further examples of compounds of formula (XIV) are compounds where R<sup>14</sup> is hydrogen, and wherein R<sup>4</sup> and R<sup>5</sup> are independently selected from hydrogen, halo or C<sub>1-6</sub>alkyl.

m is 1; R<sup>15</sup> is hydrogen or arylC<sub>1-6</sub>alkyl, R<sup>16</sup> is hydrogen or C<sub>1-6</sub>alkyl, and R<sup>17</sup> is selected from a group -E-F-G-H; wherein E, F and G are each a direct bond;

20 H is an unsaturated five membered heterocyclic group containing at least one nitrogen atom and one or two ring atoms selected from oxygen and sulphur and wherein H may be optionally substituted on carbon by one or more groups S which are independently selected from halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, ureido, C<sub>1-6</sub>alkyl, C<sub>2-6</sub>alkenyl, C<sub>2-6</sub>alkynyl, C<sub>1-6</sub>alkoxy, C<sub>1-6</sub>alkanoyl, C<sub>1-6</sub>alkanoyloxy, *N*-(C<sub>1-6</sub>alkyl)amino, *N,N*-(C<sub>1-6</sub>alkyl)<sub>2</sub>amino, C<sub>1-6</sub>alkanoylamino, *N*-(C<sub>1-6</sub>alkyl)carbamoyl, *N,N*-(C<sub>1-6</sub>alkyl)<sub>2</sub>carbamoyl, *N*-(C<sub>1-6</sub>alkyl)-*N*-(C<sub>1-6</sub>alkoxy)carbamoyl, C<sub>1-6</sub>alkylS(O)<sub>a</sub> wherein a is 0 to 2, C<sub>1-6</sub>alkoxycarbonyl, C<sub>1-6</sub>alkoxycarbonylamino, *N*-(C<sub>1-6</sub>alkyl)sulphamoyl, *N,N*-(C<sub>1-6</sub>alkyl)<sub>2</sub>sulphamoyl, C<sub>1-6</sub>alkylsulphonylamino, C<sub>1-6</sub>alkylsulphonyl-*N*-(C<sub>1-6</sub>alkyl)amino, C<sub>3-8</sub>cycloalkyl and aryl groups;

30 or a pharmaceutically acceptable salt thereof.

Other particular examples include compounds of formula (XIV) where R<sup>14</sup> is hydrogen, R<sup>4</sup> and R<sup>5</sup> are independently selected from hydrogen, halo or C<sub>1-6</sub>alkyl.

- 14 -

m is 0; and R<sup>17</sup> is a group -E-F-G-H;

wherein E is a direct bond;

F is methylene;

wherein G is -C(O)NR<sup>a</sup>-, wherein R<sup>a</sup> is selected from hydrogen or C<sub>1-6</sub>alkyl which is

5 optionally substituted by a group V ;

H is aryl which may be optionally substituted on carbon by one or more groups selected from S;

S is selected from halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, ureido, C<sub>1-6</sub>alkyl, C<sub>2-6</sub>alkenyl, C<sub>2-6</sub>alkynyl,

10 C<sub>1-6</sub>alkoxy, C<sub>1-6</sub>alkanoyl, C<sub>1-6</sub>alkanoyloxy, *N*-(C<sub>1-6</sub>alkyl)amino, *N,N*-(C<sub>1-6</sub>alkyl)<sub>2</sub>amino,

C<sub>1-6</sub>alkanoylamino, *N*-(C<sub>1-6</sub>alkyl)carbamoyl, *N,N*-(C<sub>1-6</sub>alkyl)<sub>2</sub>carbamoyl,

*N*-(C<sub>1-6</sub>alkyl)-*N*-(C<sub>1-6</sub>alkoxy)carbamoyl, C<sub>1-6</sub>alkylS(O)<sub>a</sub> wherein a is 0 to 2,

C<sub>1-6</sub>alkoxycarbonyl, C<sub>1-6</sub>alkoxycarbonylamino, *N*-(C<sub>1-6</sub>alkyl)sulphamoyl,

*N,N*-(C<sub>1-6</sub>alkyl)<sub>2</sub>sulphamoyl, C<sub>1-6</sub>alkylsulphonylamino,

15 C<sub>1-6</sub>alkylsulphonyl-*N*-(C<sub>1-6</sub>alkyl)amino, C<sub>3-8</sub>cycloalkyl, aryl and heterocyclic group; wherein S may be optionally and independently substituted on carbon by one or more groups selected from V ;

V is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxyl,

20 methylamino, ethylamino, dimethylamino, diethylamino, *N*-methyl-*N*-ethylamino,

acetylamino, *N*-methylcarbamoyl, *N*-ethylcarbamoyl, *N,N*-dimethylcarbamoyl,

*N,N*-diethylcarbamoyl, *N*-methyl-*N*-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl,


ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl,

*N*-methylsulphamoyl, *N*-ethylsulphamoyl, *N,N*-dimethylsulphamoyl, *N,N*-diethylsulphamoyl,

25 *N*-methyl-*N*-ethylsulphamoyl, morpholino, morpholinocarbonyl, *N*-benzylcarbamoyl, and 4-hydroxypiperidinocarbonyl;


or a pharmaceutically acceptable salt thereof.

Other particular compounds of formula (XIV) are compounds where the group




30 is a group of sub-formula (ii)

- 15 -



(ii)

where  $R^{14}$  is as defined above,  $R^{18}$  is aryl, substituted aryl, heteroaryl, or substituted heteroaryl,  $R^{19}$  is a bond or a group  $-\text{CH}(\text{OH})-$ , and  $R^{20}$  is a group  $-\text{C}(=\text{O})-\text{A}$  or a group  $-\text{CH}(\text{OH})-\text{C}(=\text{O})-\text{A}$  in which A is  $\text{NR}^d\text{R}^d$ ,  $-\text{NR}^a\text{CH}_2\text{CH}_2\text{OR}^a$ , or



each  $R^a$  and  $R^b$  is independently hydrogen or  $-\text{C}_1-\text{C}_8$ alkyl;

each  $R^d$  is independently hydrogen,  $\text{C}_1-\text{C}_8$ alkyl,  $\text{C}_1-\text{C}_8$ alkoxy, aryl, substituted aryl, heteroaryl, or substituted heteroaryl;

each  $R^c$  is independently hydrogen,  $-\text{C}(=\text{O})\text{OR}^a$ ,  $-\text{OR}^a$ ,  $-\text{SR}^a$ , or  $-\text{NR}^a\text{R}^a$ ; and each n is independently 1-3, and  $X^1$  is  $\text{NR}^a$ ,  $-\text{CH}_2-$ , O or S.

Examples of substituents for aryl and heteroaryl groups Q and  $R^d$  include halogen,  $\text{C}_1-\text{C}_8$ alkoxy,  $\text{C}_1-\text{C}_8$ alkyl, trifluoromethyl, amino, mono or di- $(\text{C}_1-\text{C}_8\text{alkyl})$ amino, nitro, cyano, carboxy or  $\text{C}_1-\text{C}_8$ alkyl esters thereof.

The invention will now be particularly described by way of example, in which, unless stated otherwise:

- (i) temperatures are given in degrees Celsius ( $^{\circ}\text{C}$ ); operations were carried out at room or ambient temperature, that is, at a temperature in the range of  $18-25^{\circ}\text{C}$  and under an atmosphere of an inert gas such as argon;
- (ii) organic solutions were dried over anhydrous magnesium sulphate; evaporation of solvent was carried out using a rotary evaporator under reduced pressure (600-4000 Pascals; 4.5-30 mmHg) with a bath temperature of up to  $60^{\circ}\text{C}$ ;
- (iii) chromatography means flash chromatography on silica gel; thin layer chromatography (TLC) was carried out on silica gel plates;




- (iv) in general, the course of reactions was followed by TLC and reaction times are given for illustration only;
- (v) yields are given for illustration only and are not necessarily those which can be obtained by diligent process development; preparations were repeated if more material was required;
- 5 (vi) where given, NMR data is in the form of delta values for major diagnostic protons, given in parts per million (ppm) relative to tetramethylsilane (TMS) as an internal standard, determined at 300 MHz using perdeuterio dimethyl sulphoxide (DMSO-d<sub>6</sub>) as solvent or other solvents (where indicated in the text) including deuterated chloroform CDCl<sub>3</sub>;
- (vii) chemical symbols have their usual meanings; SI units and symbols are used;
- 10 (viii) reduced pressures are given as absolute pressures in Pascals (Pa); elevated pressures are given as gauge pressures in bars;
- (ix) solvent ratios are given in volume : volume (v/v) terms;
- (x) mass spectra (MS) were run with an electron energy of 70 electron volts in the chemical ionisation (CI) mode using a direct exposure probe; where indicated ionisation was effected
- 15 by electron impact (EI), fast atom bombardment (FAB) or electrospray (ESP); values for m/z are given; generally, only ions which indicate the parent mass are reported and unless otherwise stated the value quoted is (M-H)<sup>+</sup>;

The following abbreviations are used:

- 20 DMSO = dimethylsulfoxide  
DCM = dichloromethane  
THF is tetrahydrofuran  
HPLC is high performance liquid chromatography  
DMF is dimethylformamide  
25 THF is tetrahydrofuran

### Example 1

#### Step 1



- 17 -

Thiophene-3-carbaldehyde (11.2g, 0.1M) was dissolved in dichloromethane (400ml) and cooled to 5°C. Aluminium chloride (33.25g, 0.25M) was then added in portions so that the temperature did not rise above 10°C. After the addition was complete the temperature was allowed to rise to 15°C and chlorine gas slowly bubbled into the reaction mixture. The temperature was maintained between 15 and 20°C with ice/water cooling and the reaction followed by HPLC until the mixture contained >70% of 4,5-dichlorothiophene-3-carbaldehyde.

The reaction mixture was poured into ice water (1000 ml) and the organic layer separated. The aqueous was extracted with further portions of dichloromethane (3x200ml) and the combined extracts washed with saturated sodium bicarbonate, water and brine, dried over magnesium sulphate and evaporated to give a dark oil, which crystallised on standing. Purification by recrystallisation from hexane gave 4,5-dichlorothiophene-3-carbaldehyde as light brown needles (14g, 78%). <sup>1</sup>H NMR (300MHz, d<sup>6</sup>-DMSO) 9.9 (s,1H), 8.0 (s,1H)

#### Step 2



NaOH (0.47g) was dissolved in H<sub>2</sub>O (8ml) and 4,5-dichlorothiophene-3-carbaldehyde from step 1 (1.42g) added in one portion giving a suspension. KMnO<sub>4</sub> (1.24g) was added portionwise over approximately 25 minutes whilst heating the reaction suspension in a water bath at 40°C. After complete addition the water bath temperature was raised to 50°C for a further 15 minutes stirring.

Without cooling the brown precipitate was filtered off (nylon filter) and washed with H<sub>2</sub>O. The resultant pale yellow clear solution was acidified with concentrated aqueous hydrochloric acid to give a thick white suspension. The white solid was filtered off and washed with H<sub>2</sub>O. The solid was dissolved in a mixture of ethyl acetate and dichloromethane, dried over MgSO<sub>4</sub>, filtered and evaporated under reduced pressure to leave the desired product, 4,5-dichlorothiophene-3-carboxylic acid as a white solid (1.34g). Further product was extracted from the aqueous mother liquors using dichloromethane. After drying over Na<sub>2</sub>SO<sub>4</sub>, filtration and evaporation under reduced pressure, an additional 0.19g of the desired 4,5-dichlorothiophene-3-carboxylic acid

was obtained as a white solid.  $^1\text{H}$  NMR (300 MHz,  $\text{d}^6\text{-DMSO}$ ) 13.23 (br s, 1H), 8.33 (s, 1H); ESP<sup>+</sup> 195.12

### Step 3



Under argon 4,5-dichlorothiophene-3-carboxylic acid (10.91g) was dissolved in warm dry tertiary butanol (60ml) and triethylamine (7.76ml) added followed by diphenylphosphoryl azide (DPPA) (11.99ml). The mixture was then heated slowly to reflux and refluxed for about 12 hours. On cooling the reaction mixture was poured into  $\text{H}_2\text{O}$  (~300ml). The resultant dark suspension was filtered, and the solid was washed with  $\text{H}_2\text{O}$  then dried under suction to a brown powder. This was dissolved in diethyl ether and the solution dried over  $\text{MgSO}_4$ , filtered and evaporated. Chromatography on silica gel (eluent gradient – isohexane to  $\text{CH}_2\text{Cl}_2$ ) gave *tert*-butyl (4,5-dichloro-3-thienyl)carbamate as a pale yellow solid. Yield 12.05g (78%).  $^1\text{H}$  NMR (300MHz,  $\text{CDCl}_3$ ) 7.30 (br s, 1H), 6.72 (br s, 1H), 1.51 (s, 9H)

### Step 4




The product from step 3 (445mg) was dissolved in tetrahydrofuran (THF) under an argon atmosphere, and cooled in a dry ice /acetone bath. *n*-Butyl lithium (1.6M in hexane) (2.5ml) was added dropwise and the mixture left at this temperature for 35 minutes then allowed to warm to  $-10^\circ\text{C}$  (external bath temperature) over ~ 15 minutes. Dimethylformamide (0.25ml) was then added dropwise and the temperature held at  $10^\circ\text{C}$  for 30 minutes, before being allowed to warm to room temperature. It was kept at this temperature with stirring overnight.

25 Saturated aqueous sodium chloride solution was then added, and the mixture then partitioned between ethyl acetate and water. The organic phase was dried over  $\text{MgSO}_4$ , filtered and evaporated to give a pale brown solid. Chromatography on silica gel (eluent gradient – isohexane to  $\text{CH}_2\text{Cl}_2$ ) gave *tert*-butyl (4,5-dichloro-2-formyl-3-thienyl)carbamate


as a pale yellow solid. Yield 0.31g (63%).  $^1\text{H}$  NMR (300MHz,  $\text{CDCl}_3$ ) 10.01 (s, 1H), 6.83 (br s, 1H), 1.52 (s, 9H); ESP $^-$  294.07

#### Step 5



- 5 The product from step 4 (300mg) was dissolved in dry DMF (2ml) under an argon atmosphere, and  $\text{KHCO}_3$  (102mg) was added followed by methyl bromoacetate (96 $\mu\text{l}$ ). The mixture was then heated to 60°C, for 3½ hours. After stirring overnight at room temperature, further  $\text{KHCO}_3$  (51mg) and methyl bromoacetate (48 $\mu\text{l}$ ) were added and the mixture heated at 60°C for a further 1 hour 30 minutes.
- 10 The reaction mixture was then partitioned between ethylacetate and  $\text{H}_2\text{O}$ . The organic layer was dried over  $\text{MgSO}_4$ , filtered and evaporated to a clear, orange oil. Chromatography on silica gel (eluent gradient – isohexane to  $\text{CH}_2\text{Cl}_2$  then to  $\text{Et}_2\text{O}$ ) gave methyl *N*-(*tert*-butoxycarbonyl)-*N*-(4,5-dichloro-2-formyl-3-thienyl)glycinate as a clear yellow oil (0.42g).  $^1\text{H}$  NMR (300MHz,  $\text{CDCl}_3$ ) (exists as 2:1 mixture of rotamers) 10.13 (s, 1H), 4.78 (d, 1H), 3.87 (d, 1H), 3.72 (s, 3H), 1.38 (s, 9H) (major rotamer); 10.05 (s, 1H), 4.58 (d, 1H), 3.87 (d, 1H), 3.75 (s, 3H), 1.50 (s, 9H) (minor rotamer)
- 15

#### Step 6




20

Under an argon atmosphere, the product of step 5 (746mg) was dissolved in acetic acid (5ml) and acetic anhydride (0.41ml) added. After heating for 21 hours at 120°C, the reaction mixture was evaporated under reduced pressure, and the residue partitioned between

$\text{CH}_2\text{Cl}_2$  and aqueous sodium bicarbonate solution. The organic layer was dried over  $\text{MgSO}_4$ , filtered and evaporated under reduced pressure.

- The organic layer was dried over  $\text{MgSO}_4$ , filtered and evaporated under reduced pressure. Chromatography on silica gel (eluent gradient – isohexane to  $\text{CH}_2\text{Cl}_2$  then to  $\text{Et}_2\text{O}$ :  $\text{CH}_2\text{Cl}_2$  (3:97)) gave the methyl *N*-acetyl-*N*-(4,5-dichloro-2-formyl-3-thienyl)glycinate as a clear yellow oil (34mg).  $^1\text{H}$  NMR (300MHz,  $\text{CDCl}_3$ ) 10.22 (s, 1H), 5.00 (d, 1H), 3.75 (d, 1H), 3.72 (s, 3H), 1.99 (s, 3H)

#### Step 7



The product of step 6 (103mg) under an argon atmosphere and  $\text{K}_2\text{CO}_3$  (70mg) were mixed together and dry DMF (1ml) added. The suspension quickly went red. After 2 hrs at room temperature, the temperature was raised to  $60^\circ\text{C}$  for 165 minutes. The reaction mixture was cooled to room temperature and stirred overnight.

- 15 The product was then worked-up using procedures as described in step 6, and the organic phase dried over  $\text{Na}_2\text{SO}_4$ . Chromatography on silica gel (eluent gradient – isohexane to  $\text{CH}_2\text{Cl}_2$  then to  $\text{Et}_2\text{O}$ ) gave methyl 2,3-dichloro-4*H*-thieno[3,2-*b*]pyrrole-5-carboxylate as a white solid (37mg)(45%).  $^1\text{H}$  NMR (300 MHz,  $\text{d}^6$ -DMSO) 12.86 (br s, 1H), 7.20 (s, 1H), 3.86 (s, 3H);  $\text{ESP}^+$  248.04

20

#### Step 8



The ester from step 7 (1.03g) was suspended in methanol (7.5ml) and heated to  $60^\circ\text{C}$ . A solution of  $\text{LiOH}$  (346mg, 2 eq) in  $\text{H}_2\text{O}$  was added dropwise giving an orange suspension.

- 25 After complete addition, the suspension was heated to reflux for 1 hour, whereupon it had become a clear orange solution. The reaction mixture was concentrated to almost dryness under reduced pressure, then acidified with 2M aqueous hydrochloric acid, and extracted with


- 21 -

ethyl acetate (twice). The ethyl acetate layer was dried over  $\text{MgSO}_4$ , filtered and evaporated under reduced pressure. Residual traces of MeOH were removed by azeotropeing with toluene to leave the desired 2,3-dichloro-4*H*-thieno[3,2-*b*]pyrrole-5-carboxylic acid as an off white solid (0.98g, 100%).

- 5  $^1\text{H}$  NMR (400 MHz,  $\text{d}^6$ -DMSO) 12.79 (br s, 1H), 12.63 (br s, 1H), 7.09 (s, 1H), 3.86; ESP 234.21


**Claims**

1. A process for preparing a compound of formula (I)



(I)


- where  $R^4$  and  $R^5$  are independently selected from hydrogen, halo, nitro, cyano, hydroxy, fluoromethyl, difluoromethyl, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, ureido,  $C_{1-6}$ alkyl,  $C_{2-6}$ alkenyl,  $C_{2-6}$ alkynyl,  $C_{1-6}$ alkoxy,  $C_{1-6}$ alkanoyl,  $C_{1-6}$ alkanoyloxy,  $N$ -( $C_{1-6}$ alkyl)amino,  $N,N$ -( $C_{1-6}$ alkyl) $_2$ amino,  $C_{1-6}$ alkanoylamino,  $N$ -( $C_{1-6}$ alkyl)carbamoyl,  $N,N$ -( $C_{1-6}$ alkyl) $_2$ carbamoyl,  $C_{1-6}$ alkylS(O) $_a$  wherein  $a$  is 0 to 2,  $C_{1-6}$ alkoxycarbonyl,  $C_{1-6}$ alkoxycarbonylamino,  $N$ -( $C_{1-6}$ alkyl)sulphamoyl,  $N,N$ -( $C_{1-6}$ alkyl) $_2$ sulphamoyl,  $C_{1-6}$ alkylsulphonylamino and  $C_{1-6}$ alkylsulphonyl- $N$ -( $C_{1-6}$ alkyl)amino; and  $R^6$  is hydrogen or a protecting group,
- 15 which process comprises cyclisation of a compound of formula (II)



(II)

where  $R^4$ ,  $R^5$  and  $R^6$  are as defined in relation to formula (I), and  $R^7$  is a nitrogen protecting group, and removing the group  $R^7$ , and thereafter if desired, removing any protecting group  $R^6$ .

2. A method according to claim 1 wherein  $R^7$  is a group of sub-formula (i)



(i)


where  $R^8$  is a straight chain alkyl group of from 1 to 6 carbon atoms.

3. A process according to claim 1 or claim 2 wherein  $R^4$  and  $R^5$  are independently selected from hydrogen, halo, nitro, cyano, fluoromethyl, difluoromethyl, trifluoromethyl, trifluoromethoxy, carboxy, carbamoyl, sulphamoyl, ureido,  $C_{1-6}$ alkyl,  $C_{2-6}$ alkenyl,  $C_{2-6}$ alkynyl,  $C_{1-6}$ alkoxy,  $C_{1-6}$ alkanoyl and  $C_{1-6}$ alkanoyloxy.

5


4. A compound of formula (II) as defined in claim 1.

5. A process for preparing a compound according to claim 4 which comprises reacting a compound of formula (III)



(III)

where  $R^4$  and  $R^5$  are as defined in relation to formula (I), and  $R^{12}$  is a directing nitrogen protecting group, with a compound of formula (IV)




(IV)

where  $R^7$  is as defined above, under acidic conditions.

6. A compound of formula (III) as defined in claim 5.

7. A process for preparing a compound according to claim 6 which comprises reacting a compound of formula (V)




(V)

where  $R^4$  and  $R^5$  are as defined above in claim 1 and  $R^{12}$  is as defined in relation to formula (III), with a compound of formula (VI)




- 24 -




where L is a leaving group.

5 8. A compound of formula (V) as defined in claim 7.

9. A process for preparing a compound according to claim 8 which comprises reacting a compound of formula (VII)




10 where  $R^4$  and  $R^5$  are as defined in claim 1 and  $R^{12}$  is as defined in relation to formula (III), with a lithiating agent, such as N-butyl lithium, and subsequently with a formylating agent, such as a compound of formula (VIII)



where  $R^9$  and  $R^{10}$  are alkyl groups and in particular lower alkyl groups of 1 to 4 carbon atoms,  
 15 such as methyl.

10. A compound of formula (VII) as defined in claim 9.


11. A process for preparing a compound according to claim 10 which comprises  
 20 subjecting a compound of formula (IX)



where  $R^4$  and  $R^5$  are as defined above in relation to formula (I), to a Curtius rearrangement reaction, in the presence of an alcohol of formula  $R^{12}OH$  where  $R^{12}$  is as defined in claim 5.

12. A method according to claim 1, for the production of a compound of formula (I)

5 where  $R^6$  is hydrogen, wherein the method further comprises the step of reacting the compound of formula (I) obtained with an amine of formula (XIII),



(XIII)

where  $R^{14}$  is selected from hydrogen or  $C_{1-8}$ alkyl,

10  $m$  is an integer of from 0 to 4,

each  $R^{15}$  is the same or different and is selected from hydrogen, halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, ureido,  $C_{1-6}$ alkyl,  $C_{2-6}$ alkenyl,  $C_{2-6}$ alkynyl,  $C_{1-6}$ alkoxy,  $C_{1-6}$ alkanoyl,  $C_{1-6}$ alkanoyloxy,  $N$ -( $C_{1-6}$ alkyl)amino,  $N,N$ -( $C_{1-6}$ alkyl)<sub>2</sub>amino,  $C_{1-6}$ alkanoylamino,  $N$ -( $C_{1-6}$ alkyl)carbamoyl,  $N,N$ -( $C_{1-4}$ alkyl)<sub>2</sub>carbamoyl,  $C_{1-6}$ alkylS(O)<sub>a</sub>

15 wherein  $a$  is 0 to 2,  $C_{1-6}$ alkoxycarbonyl,  $C_{1-6}$ alkoxycarbonylamino,  $N$ -( $C_{1-6}$ alkyl)sulphamoyl,  $N,N$ -( $C_{1-6}$ alkyl)<sub>2</sub>sulphamoyl,  $C_{1-6}$ alkylsulphonylamino,

$C_{1-6}$ alkylsulphonyl- $N$ -( $C_{1-6}$ alkyl)amino,  $C_{3-8}$ cycloalkyl,  $C_{3-8}$ cycloalkyl $C_{1-6}$ alkyl, aryl, aryl $C_{1-6}$ alkyl, heterocyclic group and (heterocyclic group) $C_{1-6}$ alkyl; wherein  $R^1$  may be optionally substituted on carbon by one or more groups selected from P and wherein if said

20 heterocyclic group contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R;

each  $R^{16}$  is the same or different and is selected from hydrogen or  $C_{1-6}$ alkyl;

$R^{17}$  is selected from hydrogen, halo, nitro, cyano, hydroxy, fluoromethyl,

difluoromethyl, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto,

25 sulphamoyl, ureido,  $C_{1-6}$ alkyl,  $C_{2-6}$ alkenyl,  $C_{2-6}$ alkynyl,  $C_{1-6}$ alkoxy,  $C_{1-6}$ alkanoyl,

$C_{1-6}$ alkanoyloxy,  $N$ -( $C_{1-6}$ alkyl)amino,  $N,N$ -( $C_{1-6}$ alkyl)<sub>2</sub>amino,  $C_{1-6}$ alkanoylamino,

$N$ -( $C_{1-6}$ alkyl)carbamoyl,  $N,N$ -( $C_{1-4}$ alkyl)<sub>2</sub>carbamoyl,  $N$ -( $C_{1-6}$ alkyl)- $N$ -( $C_{1-6}$ alkoxy)carbamoyl,

$C_{1-6}$ alkylS(O)<sub>a</sub> wherein  $a$  is 0 to 2,  $C_{1-6}$ alkoxycarbonyl,  $C_{1-6}$ alkoxycarbonylamino,

$N$ -( $C_{1-6}$ alkyl)sulphamoyl,  $N,N$ -( $C_{1-6}$ alkyl)<sub>2</sub>sulphamoyl, sulphamoylamino,

30  $N$ -( $C_{1-6}$ alkyl)sulphamoylamino,  $N,N$ -( $C_{1-6}$ alkyl)<sub>2</sub>sulphamoylamino,  $C_{1-6}$ alkylsulphonylamino,

C<sub>1-6</sub>alkylsulphonylaminocarbonyl, C<sub>1-6</sub>alkylsulphonyl-*N*-(C<sub>1-6</sub>alkyl)amino and a group -E-F-G-H;

wherein E and G are independently selected from a direct bond, -O-, -S-, -SO-, -SO<sub>2</sub>-, -OC(O)-, -C(O)O-, -C(O)-, -NR<sup>a</sup>-, -NR<sup>a</sup>C(O)-, -C(O)NR<sup>a</sup>-, -SO<sub>2</sub>NR<sup>a</sup>-, -NR<sup>a</sup>SO<sub>2</sub>-,  
 5 -NR<sup>a</sup>C(O)NR<sup>b</sup>-, -OC(O)NR<sup>a</sup>-, -NR<sup>a</sup>C(O)O-, -NR<sup>a</sup>SO<sub>2</sub>NR<sup>b</sup>-, -SO<sub>2</sub>NR<sup>a</sup>C(O)- and -C(O)NR<sup>a</sup>SO<sub>2</sub>-; wherein R<sup>a</sup> and R<sup>b</sup> are independently selected from hydrogen or C<sub>1-6</sub>alkyl which is optionally substituted by a group V ;

F is C<sub>1-6</sub>alkylene optionally substituted by one or more Q or a direct bond;


H is selected from aryl, C<sub>3-8</sub>cycloalkyl and heterocyclic group; wherein H may be  
 10 optionally substituted on carbon by one or more groups selected from S and wherein if said heterocyclic group contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from T;

P, S and Q are independently selected from halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, ureido,  
 15 C<sub>1-6</sub>alkyl, C<sub>2-6</sub>alkenyl, C<sub>2-6</sub>alkynyl, C<sub>1-6</sub>alkoxy, C<sub>1-6</sub>alkanoyl, C<sub>1-6</sub>alkanoyloxy, *N*-(C<sub>1-6</sub>alkyl)amino, *N,N*-(C<sub>1-6</sub>alkyl)<sub>2</sub>amino, C<sub>1-6</sub>alkanoylamino, *N*-(C<sub>1-6</sub>alkyl)carbamoyl, *N,N*-(C<sub>1-6</sub>alkyl)<sub>2</sub>carbamoyl, *N*-(C<sub>1-6</sub>alkyl)-*N*-(C<sub>1-6</sub>alkoxy)carbamoyl, C<sub>1-6</sub>alkylS(O)<sub>a</sub> wherein a is 0 to 2, C<sub>1-6</sub>alkoxycarbonyl, C<sub>1-6</sub>alkoxycarbonylamino, *N*-(C<sub>1-6</sub>alkyl)sulphamoyl, *N,N*-(C<sub>1-6</sub>alkyl)<sub>2</sub>sulphamoyl, C<sub>1-6</sub>alkylsulphonylamino,  
 20 C<sub>1-6</sub>alkylsulphonyl-*N*-(C<sub>1-6</sub>alkyl)amino, C<sub>3-8</sub>cycloalkyl, aryl and heterocyclic group; wherein P, S and Q may be optionally and independently substituted on carbon by one or more groups selected from V and wherein if said heterocyclic group contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from U;

V is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl,  
 25 amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxymethyl, methylamino, ethylamino, dimethylamino, diethylamino, *N*-methyl-*N*-ethylamino, acetylamino, *N*-methylcarbamoyl, *N*-ethylcarbamoyl, *N,N*-dimethylcarbamoyl, *N,N*-diethylcarbamoyl, *N*-methyl-*N*-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl,  
 30 *N*-methylsulphamoyl, *N*-ethylsulphamoyl, *N,N*-dimethylsulphamoyl, *N,N*-diethylsulphamoyl, *N*-methyl-*N*-ethylsulphamoyl, morpholino, morpholinocarbonyl, *N*-benzylcarbamoyl, and 4-hydroxypiperidinocarbonyl;

- 27 -

R, T and U are independently selected from C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkanoyl, C<sub>1-4</sub>alkylsulphonyl, C<sub>1-4</sub>alkoxycarbonyl, carbamoyl, *N*-(C<sub>1-4</sub>alkyl)carbamoyl, *N,N*-(C<sub>1-4</sub>alkyl)carbamoyl, phenyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl wherein R, T and U may be optionally and independently substituted on carbon by one or  
5 more groups selected from V;  
to produce a compound of formula (XIV)



(XIV)

where R<sup>4</sup>, R<sup>5</sup>, R<sup>15</sup>, R<sup>16</sup>, R<sup>17</sup> and m are as defined above, or a pharmaceutically acceptable salt  
10 or an *in vivo* hydrolysable ester thereof.

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 03/04211

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D495/04 C07D333/36 //(C07D495/04,333:00,209:00)

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data, EPO-Internal, BEILSTEIN Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No. |
|------------|--|-----------------------|
| X          | <p>SOTH, SAMRETH ET AL: "Recherches en série hétérocyclique. XXIX. Sur des voies d'accès à des thiéno, séléno, furo et pyrrolopyrroles"</p> <p>CANADIAN JOURNAL OF CHEMISTRY., vol. 56, no. 6, 1978, pages 1429-1434, XP008026687</p> <p>NATIONAL RESEARCH COUNCIL. OTTAWA., CA ISSN: 0008-4042</p> <p>scheme 3, step 15 to 13; page 1434, compound 15b</p> <p style="text-align: center;">---</p> <p style="text-align: center;">-/--</p> | 1-4                   |

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

27 January 2004

Date of mailing of the international search report

23/02/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

Alfaro Faus, I

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 03/04211

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No. |
|------------|--|-----------------------|
| X          | <p>DATABASE CA 'Online!<br/> CHEMICAL ABSTRACTS SERVICE, COLUMBUS,<br/> OHIO, US;<br/> KOBAYASHI, SHOZO ET AL: "Heterocyclic<br/> sulfonyl compounds and activated blood<br/> coagulation factor X (FXa) inhibitors<br/> containing them"<br/> retrieved from STN<br/> Database accession no. 135:313616<br/> XP002267904<br/> 368442-47-1<br/> &amp; JP 2001 294572 A (DAIICHI SEIYAKU CO.,<br/> LTD., JAPAN) 23 October 2001 (2001-10-23)</p> <p>---</p>               | 8                     |
| X          | <p>WO 02 06246 A (ISTITUTO DI RICHERCHE<br/> BIOLOGIA MOLECOLARE P. ANGELETI)<br/> 24 January 2002 (2002-01-24)<br/> page 34, compound 38</p> <p>---</p>   | 10                    |
| X          | <p>WO 94 18196 A (WELLCOME FOUNDATION)<br/> 18 August 1994 (1994-08-18)<br/> example 9A</p> <p>---</p>   | 10                    |
| X          | <p>BRUGIER, DELPHINE ET AL: "Studies on the<br/> reactivity of N-(3-thienyl)carbamates"<br/> JOURNAL OF THE CHEMICAL SOCIETY, PERKIN<br/> TRANSACTIONS 1 (2001), (1), 37-43 ,<br/> XP002267902<br/> compounds 3a,7b,15a</p> <p>---</p>   | 10                    |
| X          | <p>BOGER, DALE L. ET AL: "Total Synthesis of<br/> Distamycin A and 2640 Analogs: A<br/> Solution-Phase Combinatorial Approach to<br/> the Discovery of New, Bioactive DNA<br/> Binding Agents and Development of a Rapid,<br/> High-Throughput Screen for Determining<br/> Relative DNA Binding Affinity or DNA<br/> Binding Sequence Selectivity"<br/> JOURNAL OF THE AMERICAN CHEMICAL SOCIETY<br/> (2000), 122(27), 6382-6394 ,<br/> XP002181404<br/> compound 8a</p> | 10                    |
| X          | <p>-&amp; SUPPORTING INFO,<br/> page 1 XP002267903<br/> compound 17</p> <p>---</p>   | 10                    |
| X          | <p>BRUGIER, DELPHINE ET AL:<br/> ".alpha.-Substitution<br/> of.beta.-thienylcarbamates: alkylation,<br/> vinylation and Pd-catalyzed coupling<br/> reactions"<br/> TETRAHEDRON (2000), 56(19), 2985-2993 ,<br/> XP004198008<br/> compounds 10a, 10b, 11b</p> <p>---</p> <p style="text-align: center;">-/--</p>  | 10                    |

## INTERNATIONAL SEARCH REPORT

International application No

PCT/GB 03/04211

| C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT |   |                       |
|--|---|-----------------------|
| Category *   | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No. |
| X  | SHINKWIN, ANNE E. ET AL: "Synthesis of thiophenecarboxamides, thieno'3,4-c!pyridin-4(5H)-ones and thieno'3,4-d!pyrimidin-4(3H)-ones and preliminary evaluation as inhibitors of poly(ADP-ribose)polymerase (PARP)" BIOORGANIC & MEDICINAL CHEMISTRY (1999), 7(2), 297-308 , XP002927684 compound 8a | 10                    |
| X  | BRUGIER, DELPHINE ET AL: "Synthesis and reactivity of alkyl (4-amino-3-thienyl)carbamates" TETRAHEDRON (1997), 53(30), 10331-10344 , XP004105921 compounds 2b, 6a-6d  | 10                    |
| X  | CARROLL, WILLIAM A. ET AL: "Competitive ortho metalation effects: the kinetic and thermodynamic lithiation of 3-(tert-butoxycarbonyl)amino-4-carbomethoxythiophene" TETRAHEDRON LETTERS (1997), 38(15), 2637-2640 , XP004058292 compounds 3-1, 3-3, 6, 8  | 10                    |
| X  | SZABO, KALMAN J. ET AL: "Experimental and theoretical study of orientation in the nitration of dithieno'3,4-b:3',4'-d!pyridine" JOURNAL OF ORGANIC CHEMISTRY (1991), 56(4), 1590-6 , XP002268136 compound 5   | 10                    |
| X  | BJOERK, PATRICK ET AL: "Improved syntheses of thieno'2,3-b!- and '3,2-b!-fused naphthyridines" JOURNAL OF HETEROCYCLIC CHEMISTRY (1995), 32(3), 751-4 , XP002268137 compound 5  | 10                    |
| X  | GALVEZ ET AL: "Synthesis of thiophenedicarbonyldiazides and di-t-butyl thiophendicarbamates" JOURNAL OF HETEROCYCLIC CHEMISTRY., vol. 23, 1986, pages 1103-1108, XP002268138 HETEROCORPORATION. PROVO., US ISSN: 0022-152X compounds 1a, 1b, 13, 14   | 499                   |
|  | ---<br>-/--   |                       |

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 03/04211

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No. |
|------------|--|-----------------------|
| X          | ADAMS, JERRY L. ET AL:<br>"4-Amino-4,5-dihydrothiophene-2-carboxylic acid"<br>JOURNAL OF ORGANIC CHEMISTRY (1985),<br>50(15), 2730-6 ,<br>XP001037712<br>compound 9  | 10                    |
| X          | ---<br>GALVEZ, C. ET AL: "Synthesis of isomeric beta.-haloethylthienopyrroles"<br>JOURNAL OF HETEROCYCLIC CHEMISTRY (1984),<br>21(2), 393-5 ,<br>XP002268139<br>compound 7b  | 10                    |
| X          | ---<br>BRUNETT, EMERY W. ET AL: "Heterocyclic amines. IV. Urethan and urea derivatives of 3-aminothiophene"<br>JOURNAL OF HETEROCYCLIC CHEMISTRY (1968),<br>5(3), 417-18 ,<br>XP002268140<br>compound III  | 10                    |
| X          | ---<br>BINDER, DIETER ET AL: "Thiophen als a Strukturelement physiologisch aktiver Substanzen, 8. Mitt.<br>1H,5H-Imidazo'1,2-a!thieno'3,4-d!pyrimidin - 2(3H)-one"<br>ARCHIV DER PHARMAZIE (WEINHEIM, GERMANY) (1981), 314(6), 557-64 ,<br>XP008026782<br>compound 8 | 10                    |
| P,X        | ---<br>MARQUES, MICHAEL A. ET AL: "Toward an understanding of the chemical etiology for DNA minor-groove recognition by polyamides"<br>HELVETICA CHIMICA ACTA (2002), 85(12), 4485-4517 ,<br>XP002267901<br>page 4514, compounds 41 and 11<br>-----                  | 10                    |



# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/GB 03/04211

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

International Application No. PCT/GB 03/04211

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Present claims 5 - 11 relate to compounds defined by reference to a desirable characteristic or property, namely having a substituent R12 that is a directing nitrogen protecting group which prevents substitution on the nitrogen atom or the ring atom to which it is attached (see page 6, lines 10-12).

The claims cover all compounds having this substituent, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the compounds by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to compounds where R12 is  $-(C=O)O-R14$ , where R14 is a branched C4-10 alkyl group, or an aryl or C1-4alkylaryl group as described on page 6, lines 13-19.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International publication No  
PCT/GB 03/04211

| Patent document<br>cited in search report | Publication<br>date | Patent family<br>member(s)   | Publication<br>date  |
|---|---------------------|--|--|
| JP 2001294572 A                           | 23-10-2001          | NONE   |  |
| WO 0206246 A                              | 24-01-2002          | AU 7253001 A<br>CA 2418288 A1<br>WO 0206246 A1<br>EP 1309566 A1  | 30-01-2002<br>24-01-2002<br>24-01-2002<br>14-05-2003   |
| WO 9418196 A                              | 18-08-1994          | AU 6005194 A<br>BG 99839 A<br>CA 2155758 A1<br>CN 1117731 A<br>CZ 9502044 A3<br>EP 0683778 A1<br>FI 953777 A<br>WO 9418196 A1<br>HU 73654 A2<br>JP 8506337 T<br>MX 9401080 A1<br>SK 99195 A3<br>ZA 9400891 A | 29-08-1994<br>29-02-1996<br>18-08-1994<br>28-02-1996<br>13-03-1996<br>29-11-1995<br>09-08-1995<br>18-08-1994<br>30-09-1996<br>09-07-1996<br>31-08-1994<br>06-12-1995<br>10-08-1995 |